PREVIOUS QUESTION:

 

NEXT QUESTION:

 

What is raloxifene (Evista)?

ANSWER

Raloxifene (Evista) belongs to a class of drugs called selective estrogen receptor modulators (SERMs). It is FDA-approved for the prevention and treatment of osteoporosis in postmenopausal women and to reduce risk of invasive breast cancer in postmenopausal women at high risk or with osteoporosis.

SOURCE: National Institutes of Health. FDA news release. 

Reviewed by Melinda Ratini on September 23, 2017

SOURCE: National Institutes of Health. FDA news release. 

Reviewed by Melinda Ratini on September 23, 2017

NEXT QUESTION:

What are the effects of raloxifene?

WAS THIS ANSWER HELPFUL

THIS TOOL DOES NOT PROVIDE MEDICAL ADVICE. It is intended for general informational purposes only and does not address individual circumstances. It is not a substitute for professional medical advice, diagnosis or treatment and should not be relied on to make decisions about your health. Never ignore professional medical advice in seeking treatment because of something you have read on the WebMD Site. If you think you may have a medical emergency, immediately call your doctor or dial 911.

    This tool does not provide medical advice. See additional information.